Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
22
|
| pubmed:dateCreated |
1987-6-26
|
| pubmed:abstractText |
Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants--15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient--while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55%) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3%) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 mumol/L; mean trough, 2.38 mumol/L. Neutropenia occurred in 11 (35%) of 31 patients and in nine (60%) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0098-7484
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
12
|
| pubmed:volume |
257
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3082-7
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:3035246-Acyclovir,
pubmed-meshheading:3035246-Adolescent,
pubmed-meshheading:3035246-Adult,
pubmed-meshheading:3035246-Antiviral Agents,
pubmed-meshheading:3035246-Bone Marrow Transplantation,
pubmed-meshheading:3035246-Child, Preschool,
pubmed-meshheading:3035246-Cytomegalovirus Infections,
pubmed-meshheading:3035246-Female,
pubmed-meshheading:3035246-Ganciclovir,
pubmed-meshheading:3035246-Humans,
pubmed-meshheading:3035246-Immune System Diseases,
pubmed-meshheading:3035246-Infant,
pubmed-meshheading:3035246-Kidney Transplantation,
pubmed-meshheading:3035246-Liver Transplantation,
pubmed-meshheading:3035246-Male,
pubmed-meshheading:3035246-Middle Aged,
pubmed-meshheading:3035246-Pneumonia, Viral,
pubmed-meshheading:3035246-Postoperative Complications
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|